Nebenwirkungen · Eydenzelt
Eydenzelt 40 mg/mL solution for injection in pre-filled syringe. · Abschnitt 4.8 · PDF-Seite 8
HOS-150109 · Präparat HOS-100234
Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition. There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the aflibercept clinical trials in patients with AMD, DME, RVO and myopic CNV. Across indications no notable difference between the groups treated with aflibercept and the respective comparator groups were observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:00:00Z · SHA-256 5fe2aca986d085c341de64791e0c065aa4a6713854858d0a324ae2ac4cfa64d5 · Passage 5153a561eeb38e05552ecc8cd2e22f02750ca210a8bd4fbba941ba04a71eb2e7 · Zeichen 4677–5228 im Abschnitt